Andrzej Jakubowiak to Hematologic Diseases
This is a "connection" page, showing publications Andrzej Jakubowiak has written about Hematologic Diseases.
Connection Strength
0.049
-
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib. Br J Haematol. 2012 Sep; 158(6):739-48.
Score: 0.027
-
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
Score: 0.023